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Abstract Purified human recombinant ezrin cosediments with 
large liposomes containing phosphatidylserine (PS). This interac- 
tion is optimal at low ionic strength. At physiological ionic 
strength (130 mM KCI) ezrin interacts strongly with liposomes 
containing ~5% phosphatidylinositol-4,5-bisphosphate (PIP2), 
the residual being phosphatidylcholine (PC). When PIP2 is 
replaced by phosphatidylinositol-4-monopbosphate (PIP), phos- 
phatidylinositol (PI) or PS, the interaction is markedly reduced. 
Furthermore we show, that a purified N-terminal glutathione 
S-transferase (GST) fusion protein of ezrin (1-309) still has 
retained the capacity to interact with PIP2-containing liposomes, 
whereas a C-terminal fusion protein (310-586) has lost this 
ability. 
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1. Introduction 
Ezrin is a member of the protein 4.1-superfamily which is 
involved in the interaction of the cell cytoskeleton with the 
plasma membrane [1,2,3]. Sequence analysis shows, that ezrin 
contains an N-terminal domain with homology to protein 4.1 
and talin, followed by a long c~-helical region and a charged 
C-terminal domain [4]. The N-terminal domain of ezrin, when 
expressed in mammalian cells, locates to the plasma membrane, 
whereas the C-terminal domain is enriched in the actin cy- 
toskeleton [5], possibly via a recently identified actin binding 
site in that region [6]. Overexpressed intact ezrin accumulates 
at the plasma membrane of insect cells [7], and overexpression 
of the C-terminal site in these cells induces formation of cell 
extensions [8]. Interestingly, the N-terminal domain inhibits the 
latter effect [8]. Recently, the presence of two self-associating 
domains in ezrin, termed N- and C-ERMADs (ezrin-radixin- 
moesin association domains) has been demonstrated [9]. A pu- 
tative membrane anchor of ezrin and the closely related pro- 
teins moesin and radixin may be the cell surface glycoprotein 
CD44 [10]. The membrane association of the tyrosine kinase 
substrate zrin may be regulated by phosphorylation [3]. 
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We have now studied the interaction of human recombinant 
ezrin with phospholipids, important constituents of cell mem- 
branes, and we report on a selective interaction of ezrin with 
PIP2 via its N-terminal domain. 
2. Materials and methods 
2.1. Purification of recombinant human ezrin and domains 
Domains of ezrin were produced in E. coli as a fusion protein with 
GST and purified as described [7]. Two constructs were isolated: an 
N-terminal GST fusion protein (amino acids 1-309) and a C-terminal 
GST fusion protein (amino acids 310 586) [7]. 
2.2. Phospholipids 
PC and PS were obtained from Lipid products, South Nutfield, 
Surrey, England. PIP,, PIP and PI were obtained from Sigma, Buchs, 
Switzerland. 
2.3. Cosedimentation fezrin and ezrin domains with lipid vesicles 
Analysis of protein-lipid interactions by cosedimentation f proteins 
with large multilamellar liposomes has been documented in detail else- 
where [11]. Large, multilamellar liposomes were prepared from PC, PS, 
PI as described [11]. PIP 2 or PIP were added as stock solutions in 20 
mM Hepes pH 7.4, 0.2 mM EGTA to the dried lipids. Ezrin, and ezrin 
domains (stock solutions in 20 mM Tris/HCl, pH 7.4, 0.1 mM EDTA, 
15 mM mercaptoethanol) were centrifuged prior to the experiments for 
20 min at 20,000xg, 4°C, tbllowed by protein determination [12]. 
Proteins were subsequently incubated for 15 rain at 22°C in the absence 
of liposomes, followed by a further incubation in the absence or pres- 
ence of liposomes for 15 min. In part of the experiments, 130 mM KCI 
was included in the buffer. Proteins were kept under nitrogen during 
incubation with lipids. Final concentrations of protein were 0.1-0.15 
mg/ml and of lipid 0.5 mg/ml. The mixtures were subsequently centri- 
fuged for 20 min at 20,000 x g, 4°C. The pellets were solubilized in 
50 100 pl sample buffer [11]. The supernatants were mixed with the 
corresponding amount of the three-fold concentrated sample buffer. 
After heating the samples for 5 10 min at 95°C, they were applied to 
SDS-polyacrylamide gradient gels [13]. The amount of protein present 
in pellets and supernatants was quantified by scanning the bands of the 
Coomassie blue-stained gels. The amount of ezrin sedimented in the 
absence of liposomes was always subtracted from that sedimenting in
the presence of lipid. The data are given as mean _+ S.D. of n experi- 
ments. Differences between data were analyzed with the Student's t test 
for paired data, with a P value of <0.05 considered significant. 
2.4. Cosedimentation f chymotryptic fi'agments of ezrin with lipid 
vesicles 
Chymotryptic fragments of ezrin were generated essentially as de- 
scribed previously [14], with the following modifications. Ezrin (10 pg) 
was incubated with 0.1 pg chymotrypsin (Boehringer, Mannheim, Ger- 
many) in a buffer containing 20 mM Tris/HC1, pH 7.4, 0.1 mM EDTA, 
15 mM mercaptoethanol (final volume 30/zl) for 80 min at 22°C. The 
reaction was stopped by addition of 1 mM phenyl methyl sulfonyl 
fluoride. The fragments were then incubated and centrifuged in the 
absence or presence of liposomes (0.5 mg/ml) as described in section 2.3. 
Pellets and supernatants were applied to 5-15% gradient gels, followed 
by transfer to nitrocellulose and immunodetection [15] with a polyclo- 
hal antibody against intact human recombinant ezrin [7]. Mixtures of 
chymotryptic fragments were analyzed by FPLC in the absence of lipid 
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as follows: 200 pl of ezrin, digested as described above and adjusted to 
130 mM KC1, was applied to a Pharmacia Superdex 75 (10/30) column 
equilibrated in 20 mM Tris pH 7.4, 0.1 mM EDTA, 15 raM mercap- 
toethanol, 130 mM KCI (flow rate 0.5 ml/min; 0.5 ml per fraction). 
Fractions were analyzed by gel electrophoresis, blotting and reaction 
with a polyclonal antibody against intact ezrin, and in addition with a 
second antibody raised against he purified recombinant N-terminal 
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Fig. 1. Cosedimentation f ezrin with large liposomes of different com- 
position. (A) 7.5/lg ezrin (0.15 mg/ml) was incubated for 15 min at 22 
°C in the absence of added KC1, and in the absence or presence of large 
liposomes (0.5 mg/ml) containing different lipids, as indicated. Pellets 
(p) and supernatants ( ) were analyzed on 5-15% gradient gels. A 
Coomassie Blue-stained gel is shown. The arrow indicates ezrin. (B,C) 
Quantitative valuation of the amount of ezrin sedimenting in the 
absence (open circles) or presence (closed circles) of 130 mM KCI and 
with large liposomes containing PC and increasing amounts of PS (B) 
or PIP 2 (C), as indicated (0.5 mg/ml total lipid). 0% PS or PIP 2 corre- 
spond to 100% PC. Data correspond to the mean + S.D. of 3 experi- 
ments. 
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Fig. 2. Cosedimentation f ezrin with large liposomes containing differ- 
ent types of phospholipids. Ezrin (0.11 mg/ml) was incubated for 15 min 
at 22°C in the absence or presence of 130 mM KC1, and in the presence 
of large liposomes containig 100% PS, or 80% PC and 20% PIP2, or 20% 
PIP, 20% P], 20% PS, as indicated. After centrifugation at20,000 x g 
pellets and supernatants were analyzed by separation on 5 15% gradi- 
ent gels and scanning of the Coomassie Blue-stained bands 
(mean _+ S.D., n = 3). 
domain of ezrin as described [7]. Dilution of both antibodies was 
1 : 2000. 
Microsequencing of the chymotryptic fragments was carried out as 
described [16], at the CNRS facility in Vernaison, France. 
3. Results 
3.1. Interaction of purified intact human recombinant ezrin with 
liposomes containing different ypes of phospholipid~ 
Purified ezrin was incubated in the absence or presence of 
large multilamellar liposomes of different composition, fol- 
lowed by centrifugation at 20,000 × g. Ezrin content of pellets 
and supernatants was analyzed by SDS-PAGE and scanning of 
the Coomassie blue-stained bands. A gel of a representative 
experiment is shown (Fig. 1A). 10 30% ofezrin sedimented on 
its own in the absence of liposomes, possibly due to self-associ- 
ation [7,9]. In the presence of pure PC-liposomes. the amount 
of sedimenting ezrin was not significantly increased. In con- 
trast, in the presence of vesicles containing 100% PS, 60-85% 
of ezrin (after subtraction of ezrin sedimenting in the absence 
of lipid) was recovered in the pellet (Fig. 1A). This interaction 
was almost abolished by addition of 130 mM KCI, and by 
decreasing the% of PS in the liposomes to 20% or less. Quanti- 
tative evaluation of data is shown in Fig. 1B,C. Liposomes 
containing 20% PIP 2 and 80% PC were significantly more effi- 
cient in inducing cosedimentation f ezrin than liposomes con- 
taining the same amount of PS, and, in contrast o PS, cosedi- 
mentation with these liposomes was not abolished by 130 mM 
KC1 (Fig. 1B,C). Significantly increased association of ezrin 
could be measured for liposomes containing PC and as little as 
5 10% PIP, in the presence of 130 mM KC1 (P<0.05; Fig. 1C). 
In contrast, 10% or less of PS did not induce a significant 
association of ezrin (Fig. IB). The interactions of ezrin with 
PS-and PIP2-containing vesicles differ thus both qualitatively 
and quantitatively. The latter interaction is already optimal at 
low (~ 10%) concentrations of the lipid and is not very sensitive 
to an increase of ionic strength. 
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Fig. 3. Cosedimentation f GST-ezrin, purified GST-C- and GST-N- 
terminal domains of ezrin with large liposomes containing 20% PIP2 
and 80% PC, as compared with ezrin. GST-ezrin (GST-E), GST-N- 
terminal domain (GST-N) and GST-C-terminal domain (GST-C) (0.15 
mg protein/ml) were incubated in the absence or presence of 130 mM 
KCI, and in the presence of large liposomes containing 20% PIP2 and 
80% PC (0.5 mg lipid/ml). Incubation with lipids, centrifugation a d 
analysis of pellets and supernatants was carried out as described in the 
legend of Fig. 1. Data for ezrin from Fig. 2 are included in the Figure 
for comparison (mean + S.D. of 3~6 experiments). 
A control protein, bovine serum albumin (BSA), did not 
cosediment significantly with PS- or PIP2-containing li- 
posomes. 5% of total BSA sedimented in the presence of PS- 
liposomes compared to 2% in its absence. Moreover, preincu- 
bation of ezrin with BSA (0.15 mg/ml of each protein) did not 
affect cosedimentation f ezrin with liposomes containing 20% 
PIP 2. 46% of ezrin pelleted in the absence of BSA, versus 50% 
in its presence. 
As shown in Fig. 2, ezrin was able to discriminate between 
PIP2, PIP and PI, especially at physiological salt concentra- 
tions. Under these conditions it interacted most strongly with 
PIP2-containing liposomes. Binding to PIP-containing lipo- 
somes occurred at low ionic strength, and was decreased by 
increasing ionic strength (Fig. 2). For the experiments shown 
in Figs. 1 and 2, purified human recombinant ezrin had been 
used. GST-ezrin also interacted more strongly with PIP2, as 
compared to the other lipids (not shown). The extent of interac- 
tion of GST-ezrin with liposomes containing 20% PIP2 is shown 
in Fig. 3. Interaction under low salt conditions was comparable 
for GST-ezrin and ezrin (35 _+ 9% and 31 + 3%, respectively; 
Fig. 3). In the presence of 130 mM KC1, the extent of interac- 
tion of GST-ezrin (17 + 11%), albeit somewhat lower than that 
of ezrin (43 + 8%), was still significantly increased above back- 
ground (P < 0.005). The GST-moiety thus does not appear to 
modify substantially the lipid-binding properties of ezrin. 
3.2. Interaction of different purified domains of ezrin with 
PIPe-containing liposomes 
Interaction of the N- and C-terminal domains with liposomes 
consisting of 20% PIP#80% PC was compared in the same 
experiment with that of GST-ezrin. As shown in Fig. 3, the 
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Fig. 4. (A) Cosedimentation f chymotrypsin digestion products of 
ezrin with large lipsomes containing 10% PIP 2 and 90% PC. Recombi- 
nant ezrin (10 pg) was partially digested with chymotrypsin, i cubated 
and sedimented in the absence (1) or presence (2) of liposomes as 
described in section 2.4. Pellets (p) and supernatants (s) were analyzed 
by separation on 5-15% gradient gels and immunoblotting. A blot 
incubated with a polyclonal ntibody against human recombinant ezrin 
is shown. Numbers on the left indicate molecular masses of two major 
fragments in kDa. (B) The 34 and 19 kDa chymotrypsin digestion 
products of ezrin coelute from a Superdex 75 column. Recombinant 
ezrin was digested as described in section 2.4. Aliquots of the digestion 
products (lane E) and of fractions 19-25 eluted from the Superdex 75 
column were analyzed by gel electrophoresis and immunoblotting. 
Blots were incubated either with antibodies recognizing both N-termi- 
nal and C-terminal domains of ezrin (upper blot), or with an antibody 
recognizing only the N-terminal domain (lower blot). The indicated 
fragments of 34 and 19 kDa coeluted as a complex (peak fraction 21). 
For comparison, ote that a degradation product of the N-terminal 
domain eluted later in fractions 23-24, although its apparent molecular 
mass is higher than that of the 19 kDa peptide. 
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C-terminal domain did not interact significantly with PIP2- 
liposomes, neither in the presence nor in the absence of added 
KC1. The N-terminal domain interacted at least as strongly as 
GST-ezrin with PIP2-1iposomes in the presence of 130 mM KCI, 
but much less in the absence of added salt, in contrast o the 
intact protein (Fig. 3). 
3.3. Interaction of chymotryptic fragments of ezrin with 
PIP2-containing liposomes 
Limited chymotryptic digestion of ezrin yielded two major 
fragments of 35 and 19 kDa. Both bands reacted with the 
anti-ezrin antibody (Fig. 4A, B), but only the 35 kDa band 
reacted with the antibody directed against he N-terminal do- 
main of ezrin (Fig. 4B), indicating that the 19 kDa fragment is 
derived from the C-terminal domain. This result was confirmed 
by microsequencing of the two fragments, howing that the 35 
kDa fragment corresponded to the entire N-terminal domain 
(1-291), whereas the 19 kDa fragment corresponded tothe last 
part of the C-terminal domain (484-585). Both domains did not 
significantly pellet in the absence of lipid (Fig. 4A,1), but ap- 
proximately 60% of both the 35 kDa and the 19 kDa fragment 
cosedimented with liposomes containing 10% PIP2/90% PC 
(Fig. 4A,2). These experiments were repeated with liposomes 
containing 20% PIP2/80% PC and evaluated by scanning of the 
Coomassie Blue-stained gels. In the absence of added KC1, 
58-59% of the 35 kDa band and 48-58% of the 19 kDa frag- 
ment cosedimented with the liposomes. In the presence of 130 
mM KC1, cosedimentation f the 35 kDa fragment was reduced 
to 32~17%, and that of the 19 kDa fragment to 18 20% (n -- 2). 
Gel filtration chromatography of a mixture of the chymo- 
tryptic fragments in the absence of lipid using a Pharmacia 
Superdex 75 column showed, that the 35 and the 19 kDa frag- 
ments coelute (Fig. 4B, fraction 21). On this column, ovalbumin 
(45 kDa) elutes well before ribonuclease (13.5 kDa) suggesting 
that the two ezrin fragments derived from the N- and the 
C-terminus form a complex. 
4. Discussion 
We have demonstrated an extensive interaction of purified 
human recombinant ezrin with bilayers containing acidic 
phospholipids, and a selectivity for PIP2 revealed at physiologi- 
cal ionic strength. Interaction of ezrin with PIP2, in contrast to 
that with other related lipids such as PIP, PI, or to PS, was not 
sensitive to increasing ionic strength to 130 mM KC1, and 
occurred significantly at relatively low (5-20%) levels of PIP2 
in the bilayer and at low (/.tM) concentrations of ezrin (Figs. 1 
and 2). 20% of PIP, in mixed liposomes are required to func- 
tionally regulate gelsolin, a well-known PIP2-binding protein 
[17]. Incorporation of PIP2 into liposomes containing other 
lipids decreases, but does not abolish, the actin-severing activity 
of gelsolin, compared to the effect of pure PIP 2 micelles. It has 
been proposed, that gelsolin and also profilin bind to clusters 
of ca. five molecules on the bilayer, explaining why incorpora- 
tion of PIP2 into bilayers decreases interaction [17,18]. The total 
concentration i our experiments of PIP2 was, for liposomes 
containing 20% of this lipid, ca 100/2M. This corresponds to 
about 50 FtM exposed on the outer surface of monolamellar 
liposomes, and certainly less than 50/.tM in multilamellar li- 
posomes. In platelets, the concentration fPIP2 may be as high 
as 140-240/2M [18]. The interaction of ezrin with PIP2 occurs 
thus under physiological ionic strength and concentrations of
PIP2. Moreover, not the whole protein, but a specific domain, 
the N-terminal GST-construct of ezrin interacts electively with 
the PIP2-containing liposomes at physiological ionic strength 
(Fig. 3), another indication for a relevant interaction. Both the 
C-terminal GST-construct of ezrin, and a control protein, BSA, 
did not significantly interact with PIP2-containing liposomes. 
Interestingly, in mixtures of chymotryptic fragments of ezrin, 
a 19 kDa fragment derived from the C-terminus of ezrin also 
cosediments with PIP2-containing liposomes (Fig. 4A), in con- 
trast to the data obtained with the purified C-terminal GST- 
construct of ezrin. This may be explained by the recently de- 
scribed self-associating domains in the N- and C-terminal re- 
gions of ezrin; N-ERMAD and C-ERMAD [9]. These domains 
have been mapped to amino acids 1-296 and 479-585, respec- 
tively [9]. The chymotryptic fragment of 35 kDa (1-291) in our 
experiments thus contains the N-ERMAD, and the 19 kDa 
fragment (484-585) the C-ERMAD. We also could demon- 
strate interaction of the two fragments by FPLC (Fig. 4B). Our 
results shown in Fig. 4A may therefore be explained by the 
N-ERMAD indirectly linking the C-ERMAD to the liposomes. 
The interaction of the two domains appears not to be disturbed 
by liposome interaction of the N-terminal domain of ezrin. 
The ability of ezrin to interact directly with phospholipid 
bilayers is comparable to that of the related proteins talin and 
protein 4.1, which have also been demonstrated to interact in 
vitro via their N-terminal domain with acidic phospholipid 
bilayers [11,19]. Moreover, the interaction of protein 4.1 with 
the transmembrane protein glycophorin is enhanced by PIP2 
[20]. It will be interesting to see whether closely related amino 
acid sequences mediate lipid-interaction for all three proteins, 
and whether the interaction of ezrin with other proteins (e.g. 
actin and/or CD44) is modulated by PIP2, as described for 
different proteins regulating actin filament length or membrane 
attachment such as protein 4.1, gelsolin, profilin, ~-actinin [21]. 
Direct interaction with phospholipids has been demonstrated 
for a number of actin-associated proteins [22] and may be 
relevant also in intact cells [23]. 
In conclusion, ezrin contains in its N-terminal domain a 
phospholipid binding site which interacts in vitro with high 
affinity and under physiological conditions with bilayers con- 
taining PIP2, a molecule involved in signalling processes. This 
binding site may be involved in recruiting ezrin and the N- 
terminal domain to plasma membranes in intact cells. Interac- 
tion of the N-terminal part of ezrin with liposomes does not 
disturb N-ERMAD/C-ERMAD interaction. 
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